7.16 USD
+0.18 (+2.58%)
7.16 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to MDXG. MDXG was compared to 531 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. These ratings could make MDXG a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
In the past year MDXG had a positive cash flow from operations.
In multiple years MDXG reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.80%, MDXG belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
MDXG's Return On Equity of 17.09% is amongst the best of the industry. MDXG outperforms 95.10% of its industry peers.
With an excellent Return On Invested Capital value of 15.15%, MDXG belongs to the best of the industry, outperforming 95.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.38%, MDXG belongs to the top of the industry, outperforming 91.34% of the companies in the same industry.
MDXG has a better Operating Margin (13.73%) than 92.84% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 81.99%, MDXG belongs to the top of the industry, outperforming 85.50% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
MDXG has more shares outstanding than it did 1 year ago.
MDXG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
MDXG has an Altman-Z score of 10.23. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.23, MDXG belongs to the best of the industry, outperforming 80.98% of the companies in the same industry.
The Debt to FCF ratio of MDXG is 0.27, which is an excellent value as it means it would take MDXG, only 0.27 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MDXG (0.27) is better than 95.29% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
The Debt to Equity ratio of MDXG (0.07) is worse than 62.52% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 10.23 |
ROIC/WACC1.75
WACC8.68%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.09% of its industry peers.
A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio (3.95) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
The Earnings Per Share is expected to grow by 16.54% on average over the next years. This is quite good.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 14.49% on average per year.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MDXG is valuated rather expensively with a Price/Earnings ratio of 19.89.
Based on the Price/Earnings ratio, MDXG is valued cheaper than 94.35% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.76, MDXG is valued a bit cheaper.
With a Price/Forward Earnings ratio of 28.65, MDXG can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 92.66% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.96. MDXG is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 28.65 |
4.2 Price Multiples
MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 95.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 96.05% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.87 | ||
| EV/EBITDA | 13.64 |
4.3 Compensation for Growth
MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MDXG may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.16
+0.18 (+2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.78%
Inst Owner Change-0.7%
Ins Owners1.79%
Ins Owner Change0.17%
Market Cap1.06B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (73.74%)
Short Float %3.22%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)-1.18%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0.96%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 28.65 | ||
| P/S | 2.7 | ||
| P/FCF | 15.87 | ||
| P/OCF | 15.63 | ||
| P/B | 4.44 | ||
| P/tB | 5.09 | ||
| EV/EBITDA | 13.64 |
EPS(TTM)0.36
EY5.03%
EPS(NY)0.25
Fwd EY3.49%
FCF(TTM)0.45
FCFY6.3%
OCF(TTM)0.46
OCFY6.4%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.42
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 10.23 |
F-Score6
WACC8.68%
ROIC/WACC1.75
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.89 and the Price/Book (PB) ratio is 4.44.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.